Table 3.

Extract of base-case health economic results.

Intervention (design, cancer)		Time horizon	Currency, year	Δ QALYsa/person (95% CI)	Δ Costs/person (95% CI)		Deterministic ICERb/result		WTPc: CE%d	DRe (%)
Cost-effectiveness
	eRAPID [6] (hybrid, multiple)	18 weeks	GBP, 2018	0.003 (–0.005 to 0.011)	–£25 (–£1241 to £1167)		eRAPID dominates		£20,000: 55%; £30,000: 58%	0
	STAR [39] (active, solid)	Lifetime (10 years)	CAD, —f	0.25	$3363		$13,450		$50,000: 90.8%	1.5
	Sentinel [34] (active, lung)	Trial (20 months)	EUR, —	Per-person: — (cohort-level: 4.59g)	€1963 (€1446 to €2480)		€20,912		€30,000: 97%; €90,000: 100%	0
	Interaktor [79] (hybrid, multiple)	6 months	EUR, 2022	0.0076	€1454		€13,213 to €202,368		—	0
	Oncokompas [78] (reactive, multiple)	6 months	EUR, 2017	0.0017 (–0.0121 to 0.0155)	–€163 (–€665 to €326)		Oncokompas dominates		—	—
Cost-consequence and budget impact
	Affordable Better [70] (reactive, colorectal)	1 year	EUR, —	N/Ah	Per-person: –€190 (Calculated from cohort-level: –€22,000g)		Cost-saving		N/A	N/A
	CAPRI [37] (reactive, multiple)	Trial (4.58 months)	EUR, 2022	N/A	–€377		Cost-saving		N/A	N/A
	The Programme [85] (N/A, prostate)	8 months	GBP, 2015	N/A	–£37		Cost-saving		N/A	N/A
Health resource use analyses
	PROMPT-Care [5] (active, multiple)	Trial (30 months)	N/A	N/A	N/A		Emergency department visits reduced by 33% (P=.02), but no significant difference in outpatient HRUi	N/A		N/A
	SIS.NET [83] (hybrid, breast)	Trial (18 months)	N/A	N/A	N/A	No significant differences in rates of HRU (outpatient and test/scans)		N/A		N/A

^aQALY: quality-adjusted life year.

^bICER: incremental cost-effectiveness ratio.

^cWTP: willingness-to-pay (threshold).

^dProbability of cost-effectiveness

^eDR: discount rate.

^fNot available.

^gSummed values for entire cohort instead of per person estimates.

^hN/A: not applicable.

ⁱHRU: health resource use.